Improvement of accuracy and diagnostic significance of breast tumor fine-needle aspiration biopsy by miRNA analysis of material isolated from cytological smears

Relevance. Breast cancer is the most commonly diagnosed cancer in women. Tumor biopsy, a key diagnostic approach, is required to evaluate the nature of tumor and to determine the therapeutic strategy. In clinical practice methods are being applied: trepan-biopsy and fine needle aspiration biopsy (FNAB). The latter is less traumatic however is used less often because it provides with less information. Moreover, dependence from quality of biopsy and qualification of morphologist are attributes of both techniques. A possibility to use biopsy material for farther analysis of tumor-markers would open a perspective to obtain more information and to improve objectivity of traditional diagnostic approaches, including FNAB. MicroRNAs (miRNAs), regulatory molecules involved in control of virtually all physiologic and pathologic process, emerged as promising tumor markers. Malignant transformation of mammary gland epithelia is associated with specific alterations of cellular miRNAs profile. Analysis of these alterations is of great diagnostic potency.

Objective. Development of method for miRNAs analysis in cytological smears material and evaluation of its practical applicability.

Material and methods. Archived cytological material (smears on the glass slides) from patients with benign tumor and breast cancer was used. Analysis of miRNAs expression was performed by reverse transcription followed by quantitative PCR. Results of reverse transcription polymerase chain reaction were analyzed with use of relevant cytological and morphological data.

Results. Method of miRNAs analysis in material of cytological smears was developed. Expression of 9 miRNAs in 80 samples was evaluated. Statistically significant expression difference between benign and malignant tumor samples was found for 5 miRNAs: miR-21, miR-205, miR-125b, miR-200a, miR-221. MiR-125b exhibited most prominent expression dysregulation: malignant transformation of mammary epithelium is associated with 500 fold decrease of miR-125b expression level. Expression alterations of several miRNAs were revealed to correlate with clinically relevant characteristics of tumors.

Conclusions. Results of our study indicated the possibility of miRNAs expression analysis in the FNAB material and the applicability of this method as additive approach to the convention cytological examination. Application of this method will allow to specify diagnosis and to optimize choice of the therapeutic strategy.

1. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П.А. Герцена»

2. Минздрава России, 2014. [Kaprin А.D., Starinskiy V.V., Petrovа G.V. Malignant neoplasms in Russia in 2012 (morbidity and fatality). Мoscow: P.A. Herzen Moscow Cancer Research Institute, Ministry of Health of Russia, 2014. (In Russ.)].

3. Stolier A., Skinner J., Levine E.A. A prospective study of seeding of the skin after core biopsy of the breast. Am J Surg 2000;180(2):104–7.

4. Di Leva G., Garofalo M., Croce C.M. MicroRNAs in cancer. Annu Rev Pathol 2014;9:287–314.

5. Kolesnikov N.N., Titov S.E., Veriaskina Iu.A. et al. MicroRNA, evolution and cancer. Tsitologiia 2013;55(3):159–64.

6. Takahashi R.U., Miyazaki H., Ochiya T. The Roles of MicroRNAs in Breast Cancer. Cancers 2015;7(2):598–616.

7. Bertoli G., Cava C., Castiglioni I. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics 2015;5(10):1122–43.

8. Graveel C.R., Calderone H.M., Westerhuis J.J. et al. Critical analysis of the potential for microRNA biomarkers in breast cancer management. Breast Cancer 2015;7:59–79.

9. Bhattacharyya M., Nath J., Bandyopadhyay S. MicroRNA signatures highlight new breast cancer subtypes. Gene 2015;556(2):192–8.

10. Веряскина Ю.А., Титов С.Е., Родионов В.В. др. Экспрессия микроРНК в молекулярно-генетических подтипах рака молочной железы. Современные проблемы науки и образования 2015;5. [Veryaskinа Yu.А., Тitov S.Е., Rodionov V.V. et al. MicroRNA experssion in molecular & genetic subtype of the mammary gland cancer. Sovremennye problemy nauki i obrazovaniya = Modern Science and Education Problems 2015;5. (In Russ.)].

11. Gasparini P., Cascione L., Fassan M. et al. MicroRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget 2014;5(5):1174–84.

12. Kolacinska A., Morawiec J., Fendler W. et al. Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report. Mol Biol Rep 2014;41(5):2851–7.

13. Ouyang M., Li Y., Ye S. et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer. PloS One 2014;9(5):e96228.

14. Harquail J., Benzina S., Robichaud G.A. MicroRNAs and breast cancer malignancy: an overview of miRNAregulated cancer processes leading to metastasis. Cancer Biomark 2012;11(6):269–80.

15. Tanic M., Yanowski K., Andres E. et al. MiRNA expression profiling of formalinfixed paraffin-embedded (FFPE) hereditary breast tumors. Genom Data 2015;3:75–9.

16. Kolacinska A., Morawiec J., Pawlowska Z. et al. Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients. DNA Cell Biol 2014;33(9):624–9.

17. Phuong N.T., Kim S.K., Im J.H. et al. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells. Oncotarget 2015.

18. Calvano Filho C.M., Calvano-Mendes D.C., Carvalho K.C. et al. Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR- 17-5p, and miR-20a-5p. Tumour Biology 2014;35(8):7733–41.

19. Xu F., He H., Huang W. et al. Decreased expression of MicroRNA-200 family in human breast cancer is associated with lymph node metastasis. Clin Transl Oncol 2016;18(3):283–8.

20. Tsouko E., Wang J., Frigo D.E. et al. MiR-200a inhibits migration of triplenegative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis 2015;36(9):1051–60.

21. Usmani A., Shoro A.A., Memon Z. et al. Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals. Am J Cancer Res 2015;5(8):2484–90.

22. Eissa S., Matboli M., Sharawy A., El-Sharkawi F. Prognostic and biological significance of microRNA-221 in breast cancer. Gene 2015;574(1):163–7.

23. Li Y., Liang C., Ma H. et al. MiR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 2014;19(6):7122–37.

24. Yu D.D., Lv M.M., Chen W.X. et al. Role of miR-155 in drug resistance of breast cancer. Tumour Biol 2015;36(3):1395–401.

25. Zhang H., Fan Q. MicroRNA-205 inhibits the proliferation and invasion of breast cancer by regulating AMOT expression. Oncol Rep 2015;34(4):2163–70.

26. Vilquin P., Donini C.F., Villedieu M. et al. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. Breast Cancer Res 2015;17:13.

27. Hurst D.R., Edmonds M.D., Scott G.K. et al. Breast cancer metastasis suppressor 1 up-regulates miR-146, which suppresses breast cancer metastasis. Cancer Res 2009;69(4):1279–83.